Дифференцированная тактика ведения больных с генитальным герпесом

1. Адаскевич В.П. Заболевания, передающиеся половым путем. Витебск, 1997.
2. Владимирова Е.В. Эффективность фамцикловира в лечении рецидивирующего генитального герпеса (клинико-лабораторное исследование): Дис. … канд. мед. наук. М., 1998.
2. Кожные и венерические болезни. Руководство. Том 1. Под ред. Ю.К. Скрипкина М., 1995.
3. Лимфомы кожи. Урогенитальная герпесвирусная инфекция (под ред. Соколовского Е.В.). СПб., 2000.
4. Марченко Л.А. Генитальный герпес у женщин (клиника, диагностика, лечение). Materia medica 1996; 2: 53–73.
5. Посевая Т.А., Цукерман В.Г., Шуваева Н.И. Роль герпетической инфекции при эпителиальных дисплазиях шейки матки и опыт их лечения противогерпетическими препаратами. Вопр. вирусол. 1991; 6: 649.
6. Пухнер А.Ф., Козлова В.И. Вирусные заболевания гениталий. М.: Медицина, 1975.
7. Сельков С.А., Айламазян Э.К. Генитальный герпес: современные подходы к диагностике и терапии. СПб., 2000; 7 (1): 34–41.
8. Семенова Т.Б., Губанова Е.И., Яцуха М.В., Рыбакова Е.Ю. Эпидемиологические аспекты генитального герпеса. Анализ заболеваемости генитальным герпесом в Российской Федерации и в г. Москве за период с 1994 по 1998 г. ИППП. 2000; 6: 26–30.
9. Сидельникова В.М. Невынашивание беременности. М.: Медицина, 1986.
10. Терешин А.Т. Клиника, диагностика и лечение генитального герпеса у женщин. Пятигорск, 1999; 17.
11. Щербо С.Н. Лабораторная медицина. 1998; с. 181–3.
12. Acyclovir suppression to prevent cesarean delivery after first- episode genital herpes. Obsetet Gynecol 1996; 87: 69–73.
13. Armstrong GL, Schillinger J, Markowitz L et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001; 153: 912–20. (Level II-3).
14. Ashley RL, Cent A, Maggs V et al. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991; 115 (7): 520–6. (Level II-3).
15. Ashley RL, Militoni J, Lee F et al. Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26: 662–7.
16. Ashley RL. Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin Med 1993; 69: 174–83. (Level III).
17. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77: 232–7. (Level III).
18. Ashley-Morrow R, Krantz E, Wald A. Time course of sero- conversion by HerpeSelect ELISA after acquisition of gen ital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30: 310–4. (Level II-3).
19. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121: 847–54.
20. Brown ZA, Selke SA, Zeh J et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337: 509–15. (Level II-2).
21. Carney O, Ross E, Bunker C et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994; 70: 40–5.
22. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2002. Atlanta (GA): CDC; 2003. (Level II-3).
23. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 57, November 2004.
24. Corey L, Benedetti J, Critchlow C et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983; 12 (suppl B): 79–88. (Level I).
25. Corey L, Mindel A, Fife KH et al. Risk of recurrence after treatment of first episode genital herpes with intravenous acyclovir. Sex Transm Dis 1985; 12: 215–8. (Level I).
26. Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. Valacyclovir HSV Transmission Study Group. N Engl J Med 2004; 350: 11–20. (Level I).
27. Corey L, Langenberg AGM, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized, controlled trials. JAMA 1999; 282: 331–40.
28. Corey L, Wald A. New development in the biology of genital herpes. In: Clinical management of Herpes Virus Infections. Eds. S.L. Sacks, S.E. Straus, R.J. Withey, P.D. Griffiths. Netherlands: IOS Press 1995; 43–53.
29. Deviant Beh * avior: An Interdisciplinary Journal 2000; 21: 95–121.
30. Douglas Jm, Critchlow C, Benedetti J et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310: 1551–6.
31. Fife KH, Corey L. Herpes simplex virus. In: Holmes KK, ed. Sexually Transmitted Diseases, 2nd edn, Chap 77. New York: McGraw-Hill, 1990; 941–52.
32. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337: 1105–11.
33. Fortenberry JD. McFarlane M. Bleakley A, et al. Relationships of stigma and shame to gonorrhea and human immunodeficiency virus screening. Am J Public Health 2002; 92: 378–81.
34. Goldberg LH, Kaufman R, Kurtz TO et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993; 129: 582–7.
35. Goodyear HM, Wilson P, Cropper L et al. Clin Exp Dermatol 1994; 19 (4): 294–7.
36. Immunodeficiency virus post-test counseling by telephone for low risk clients of an urban sexually transmitted diseases clinic. Se? Transm Dis 1996; 23: 190–7.
37. Jerome KR, Huang ML, Wald A et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40: 2609–11. (Level III).
38. Johnson RE, Nahmias AJ, Magder LS et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321: 7–12.
39. Kudesia G, Van Hegan A, Wake S et al. Comparison of cell culture with an amplified enzyme immunoassay for diagnosing genital herpes simplex infection. J Clin Pathol 1991; 44: 778–80.
40. Langenberg AG, Corey L, Ashley RL et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341: 1432–8. (Level I).
41. Melville J, Sniffen S, Crosby R et al. Psychosocial impact of sero-logical diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect 2003; 79: 280–5. (Level III).
42. Mertz GJ, Jones CC, Mills J et al. Long-term acyclovi suppression offrequently recurring genital herpes simplex vin< infection. A multicenter double-blind trial. JAM 1988; 260: 201–6.
43. Mertz GL, Benedetti J, Ashley R et al. Risk factor for sexual transmission of genital herpes. Ann Intern Med 1992; 116: 197–202.
44. Nack A. Damaged goods: Women managing the stigma of STDs. Deviant Beh * avior: Interdisciplinary J 2000; 21: 95–121.
45. Patel R, Tyring S, Strand A et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75: 398–402. (Level II–3).
46. Prober CG, Hensleigh PA, Boucher FD et al. Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med 1988; 318: 887–91.
47. Prober CG, Sullender WM, Yasukawa LL et al. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes. N Engl J Med 1987; 316: 240–4.
48. Romanowski B, Marina RB, Roberts JN. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Valtrex HS23ool7 Study Group. Sex Transm Dis 2003; 30: 226–31. (Level II–3).
49. Sacks SL, Hughes A, Rennie B, Boon R. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: a randomized double-blind, double-dummy, parallel-group, placebo-controlled trial. In: Program and abstracts of the 37th interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 – October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997; 227 (abstract).
50. Slomka MJ, Emery L, Munday PE et al. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998; 55: 177–83. (level II-3).
51. Spruance SL, Tyring SK, DeGregorio B et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch intern Med 1996; 156: 1729–35.
52. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. GlaxoSmithKline Herpes Vaccine Efficacy Study Group. N Engl J Med 2002; 347: 1652–61. (Level I).
53. Fortenberry JD, McFarlane M, Bleakley A et al. Relationships of stigma and shame to gonorrhea and human immunodeficiency virus screening. Am J Public Health 2002; 92: 378–81.
54. Munday PE, Vuddamalay J, Slomka MJ, Brown DW. Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Sex Transm Infect 74: 175–8.
55. Patel R, Strand A, Crooks RJ. Virological evidence that valaciclovir aborts genital herpes simplex virus lesions (abstract 106). In: Program and abstracts of STIs at the Millennium: Past, Present, and Future. Medical Society for the Study of Venereal Diseases/American Sexually Transmitted Diseases Associanion 2000; 15.
56. Waddell R. Genital HSV infection: long-term approacbes for a lifelong disease. Herpesvirus infections: new paradigms for a new millennium. P. 10–7.
57. Wald A, Zeh J, Barnum G et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124: 8–15. (Level II–3).
58. Wald A, Huang ML, Carrell D et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188: 1345–51. (Level III).
59. Wald A, Langenberg AG, Link K et al. Effect of condoms on reducing the trans mission of herpes simplex virus type 2 from men to women. JAMA 2001; 285: 3100–6. (Level II-2).
60. Wald A, Corey L, Cone R et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997; 99: 1092–7.
61. Wald A, Zeh J, Selke S. Virologic characteristics of subclinical and symptomatic genital herpes infection. N Engl J Med 1995; 333: 770–5.

Л.А.Марченко, И.П.Лушкова

Научный центр акушерства, гинекологии перинатологии (дир. – акад. РАМН В.И.Кулаков) РАМН, Москва